Patient Access Analytics

MMIT's Patient Access Analytics solution brings together the power of integrated analytics - where for the first time in the life sciences industry, payer coverage data, patient claims data, institutional pathways data and lab testing data has been brought together to deliver actionable insights that will enable pharmaceutical manufacturers to move even closer to the patient.

Over the past few decades, pharma companies have perfected the art of using market access data to support product launches, negotiate payer discounts, and secure preferred status and positioning. Manufacturers typically track formulary and medical policy guidelines and restrictions—including prior authorization and step therapy requirements—for a product and its competitors, using this data to inform their market access strategy.

For the most part, this approach works. But in competitive therapeutic areas, like immunology and oncology, optimizing patient access, depends on creating a more structured, holistic market access story. By augmenting traditional datasets with real-world data, manufacturers can follow patients’ progression along the care continuum—and uncover new opportunities to improve access.

Integrating real-world lab and claims data with coverage and clinical pathways data reveals a new world of opportunity for manufacturers. With full visibility into how patients receive care, manufacturers can maximize the ratio of diagnosed patients to treated patients—and optimize access to their therapies.